

---

# **Mechanisms of Osteoarthritis: Interrelationships between Bone and Cartilage**

A Thesis submitted to The University of Adelaide in fulfilment of the  
requirements for the degree of Doctor of Philosophy

By

**Geetha Mohan, M.Phil**

Discipline of Anatomy and Pathology, School of Medical Sciences

The University of Adelaide

Bone and Joint Research Laboratory, Directorate of Surgical Pathology,

SA Pathology, Adelaide

**March 2012**

---

---

## TABLE OF CONTENTS

Abstract	i
Declaration	iv
Acknowledgments	v
Published abstracts	vii
Scientific communication	viii
Awards	xii
Abbreviations	xiii
<b>Chapter 1 Literature review and project aims</b>	<b>1</b>
<b>1. Introduction</b>	<b>2</b>
<b>1.1. The knee joint</b>	<b>2</b>
<b>1.2. Aetiopathology of osteoarthritis (OA)</b>	<b>5</b>
<b>1.3. Articular cartilage</b>	<b>5</b>
1.3.1. Structural organisation of normal articular cartilage	6
1.3.2. Composition of articular cartilage	8
1.3.2.1. Chondrocytes	8
1.3.2.2. Collagen	8
1.3.2.3. Proteoglycans	10
1.3.3. Pathological changes in OA cartilage matrix	10
1.3.4. Alteration in OA articular cartilage metabolism	11
1.3.5. Cellular changes in OA cartilage	13
<b>1.4. Subchondral bone</b>	<b>15</b>
1.4.1. Normal structure of the subchondral plate	16
1.4.2. The osteochondral junction	17
1.4.3. Vascularity of the subchondral bone plate	19
1.4.4. Subchondral plate thickness and density distribution	19
1.4.5. Pathological changes in OA subchondral bone	20
1.4.6. Subchondral bone remodelling in OA	21
1.4.7. OA related changes in trabecular microarchitecture	23
1.4.8. Biochemical changes of subchondral bone in OA	24
1.4.9. Hypomineralisation of bone in OA	25
1.4.10. Biochemical properties of bone	26
1.4.11. Biomechanical adaptation: Osteophyte formation	27
1.4.12. Subchondral bone cyst formation in OA	30
1.4.13. Bone marrow lesion (BMLs) in OA	33

---

---

<b>1.5. Bone-cartilage interaction</b>	<b>34</b>
1.5.1. Molecular cross-talk between bone and cartilage	36
1.5.2. Key regulators of bone remodelling: the RANK/RANKL/OPG System	37
1.5.2.1. OPG	38
1.5.2.2. RANK	38
1.5.2.3. RANKL	39
<b>1.6. Bisphosphonates as disease modifying OA drugs (DMOADs)</b>	<b>40</b>
1.6.1. Structure of Bisphosphonates	41
1.6.2. Mechanism of action of bisphosphonate	43
1.6.3. Biological activity of nitrogen containing bisphosphonates: with reference to alendronate	43
1.6.4. Bisphosphonate treatment for OA	44
<b>1.7. Animal models of OA</b>	<b>50</b>
1.7.1. Commonly used animal species	50
1.7.2. Type of OA induction	51
1.7.3. Monosodium iodoacetate-induced experimental OA model	52
1.7.4. Dose response study	53
<b>1.8. <i>In vivo</i> micro-CT tomography (micro-CT) assessment of bone in rodent models of OA</b>	<b>55</b>
1.8.1. <i>In vivo</i> micro-CT imaging of cartilage in rodent models of OA	56
1.8.2. Consideration for <i>in vivo</i> micro-CT imaging of rodents	57
<b>1.9. Research aims</b>	<b>58</b>
1.9.1. Project aims	60
<b>2. Chapter 2 Application of <i>in vivo</i> micro-computed tomography in the temporal characterisation of subchondral bone architecture in a rat model of low-dose monosodium iodoacetate induced osteoarthritis</b>	<b>61</b>
<b>2.1. Introduction</b>	<b>66</b>
<b>2.2. Materials and methods</b>	<b>66</b>
2.2.1. Animal and OA induction	66
2.2.2. <i>In vivo</i> micro-CT imaging	67
2.2.3. Bone histomorphometric analysis	67
2.2.3.1. Subchondral trabecular bone	67
2.2.3.2. Subchondral plate	68
2.2.4. Macroscopic analysis	68
2.2.5. Histological analysis	68
2.2.6. Serum C-reactive protein (CRP) analysis	68
2.2.7. Statistical analysis	68

---

---

<b>2.3. Results</b>	<b>68</b>
2.3.1. Micro-CT	68
2.3.1.1. Bone histomorphometric changes	68
2.3.1.2. Subchondral trabecular bone	69
2.3.1.3. Subchondral plate	69
2.3.1.4. Qualitative subchondral bone changes	69
2.3.2. Macroscopy	69
2.3.3. Histology	72
2.3.4. Serum CRP levels	72
<b>2.4. Discussion</b>	<b>73</b>
<b>2.5. Conclusions</b>	<b>76</b>
<b>3. Chapter 3 Pre-emptive, early, and delayed alendronate treatment in a rat model of low-dose monosodium iodoacetate induced osteoarthritis: effect on subchondral trabecular bone microarchitecture, cartilage degradation, bone and cartilage turnover, and joint discomfort</b>	<b>79</b>
<b>3.1. Introduction</b>	<b>86</b>
<b>3.2. Materials and methods</b>	<b>88</b>
3.2.1. Animals and OA induction	88
3.2.2. Alendronate (ALN) treatment	89
3.2.3. <i>In vivo</i> micro-CT analysis	90
3.2.4. Hind limb weight-bearing (HLWB) assessment	91
3.2.5. Macroscopic analysis	92
3.2.6. Histological analysis	92
3.2.7. Serum COMP, CTX-I and urine CTX-II analysis	93
3.2.8. Statistical analysis	93
<b>3.3. Results</b>	<b>94</b>
3.3.1. <i>In vivo</i> micro-CT: subchondral trabecular bone Histomorphometry	94
3.3.1.1. Effect of pre-emptive ALN treatment	94
3.3.1.2. Effect of early ALN treatment	95
3.3.1.3. Effect of delayed ALN treatment	96
3.3.2. Effect of ALN on hind limb weight-bearing	98
3.3.3. Effect of ALN on macroscopic cartilage changes	98
3.3.4. Effect of ALN on microscopic cartilage changes	99
3.3.5. Effect of ALN on subchondral trabecular bone mineral apposition rate (MAR)	101
3.3.6. Effect of ALN on serum COMP, CTX-I and urine CTX-II	101
<b>3.4. Discussion</b>	<b>101</b>
<b>3.5. Conclusions</b>	<b>107</b>

---

---

<b>4. Chapter 4 Alendronate modulates gene expression of osteoprotegerin and receptor activator of nuclear factor <math>\kappa</math>B ligand in subchondral bone in the early phase of experimental osteoarthritis</b>	<b>126</b>
<b>4.1. Introduction</b>	<b>132</b>
<b>4.2. Materials and methods</b>	<b>134</b>
4.2.1. Animals and OA induction	134
4.2.2. Alendronate (ALN) treatment	135
4.2.3. Tissue preparation	135
4.2.4. Total RNA isolation and cDNA synthesis	136
4.2.4.1. Real-time RT-PCR	137
4.2.5. Statistical analysis	138
<b>4.3. Results</b>	<b>138</b>
4.3.1. Target gene expression within the OA group	139
4.3.2. Target gene expression within the ALN treatment group	139
4.3.3. Effect of ALN treatment on RANK, RANKL, and OPG mRNA expression	140
4.3.4. Effect of ALN on tibial subchondral bone histomorphometric parameters	141
<b>4.4. Discussion</b>	<b>141</b>
<b>4.5. Conclusions</b>	<b>147</b>
<b>5. Chapter 5 Discussion</b>	<b>157</b>
5.1. Overview of study findings	159
5.2. Comparison to existing literature	160
5.3. Strengths and limitations	167
5.4. Areas for further research and clinical implications	168
5.5. Conclusion	171
<b>Appendices</b>	<b>172</b>
Appendix I: A dose response study in the monosodium iodoacetate rat model of osteoarthritis: <i>in vivo</i> micro-CT, histological and serological evaluation	173
Appendix II: Development of an <i>in vivo</i> scanning protocol for tracking temporal changes in tibial subchondral bone in a low-dose MIA-induced OA rat model	201
<b>References</b>	<b>221</b>

---

---

## ABSTRACT

Osteoarthritis (OA) is a progressive joint disease and a common cause of disability. OA is characterised by loss of articular cartilage, subchondral bone sclerosis, cysts, and osteophyte formation. Increased subchondral bone remodelling plays an important role in the pathophysiology of OA and is associated with disease progression. It is known that Osteoprotegerin (OPG), receptor activator of nuclear factor kappa b (RANK) and its ligand RANKL tightly control bone remodelling. In addition, RANK, RANKL and OPG gene expression has been shown to be dysregulated in human OA subchondral bone.

Commonly OA is diagnosed at advanced stages, which makes it difficult to study the initiating events in the human disease. Animal models of OA are of considerable importance to study the progressive changes in OA, and to evaluate suitable OA drugs. Alendronate (ALN) is a potent bone resorption inhibitor and clinical trials using bisphosphonates to treat OA have yielded mixed results. This suggests that the effects of bisphosphonates may or may not be beneficial depending on the stage of OA progression.

The first aim of this thesis was to characterise the temporal structural changes of tibial articular cartilage and subchondral bone in a low-dose MIA-induced OA rat model. The results from micro-CT analysis showed that the tibiae of the MIA-injected knees had significant bone loss at 2 weeks (early OA), followed by increased bone volume, trabecular thickness and separation at 6 weeks (intermediate OA) and 10 weeks

---

(advanced OA). Micro-CT images revealed subchondral bone sclerosis, cysts, and osteophyte formation at 6 and 10 weeks. Histology revealed progressive cartilage degradation characteristic of the human disease.

The second aim of this thesis was to study the effect of ALN treatment initiated at day 0 (pre-emptive), week 2 (early treatment), and week 6 (delayed treatment) in a low-dose MIA rat model. To address the second aim the efficacy of ALN was tested on cartilage degradation, subchondral bone remodelling, and joint discomfort observed in this animal model. The study demonstrated that pre-emptive ALN treatment preserved subchondral trabecular bone microarchitecture, decreased bone turnover, prevented joint discomfort, and offered moderate chondroprotection. Early and delayed ALN treatment prevented loss of trabeculae and decreased bone turnover but did not have any identified effect on cartilage.

Finally, the RANK, RANKL, OPG gene expression in OA was characterised in a low-dose MIA rat model. The effect of ALN treatment on subchondral bone RANK, RANKL, and OPG gene expression at 2, 6, and 10 weeks after OA induction was assessed. This study showed that the RANKL and OPG gene expression was dysregulated in this animal model. In addition, the efficacy of ALN on early subchondral bone changes appears to occur through the modulation of RANKL and OPG gene expression.

---

Collectively, these findings demonstrate that the low-dose MIA rat model closely mimics the pathological features of progressive human OA disease. Moreover, this animal model showed a clear relationship between the cartilage damage and subchondral bone changes. ALN treatment preserved subchondral trabecular bone microarchitecture and decreased bone turnover. In addition, ALN prevented RANKL and OPG gene dysregulation in OA subchondral bone. Normalising subchondral bone remodelling offers an optimal treatment option and future drug intervention studies focusing on subchondral bone would provide improved treatment options for OA.



---

## DECLARATION

I, Geetha Mohan certify that this work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, this thesis contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968. The author acknowledges that copyright of published works contained within this thesis (as listed below) resides with the copyright holder(s) of those works.

**Mohan G**, Perilli E, Kuliwaba JS, Humphries JM, Parkinson IH, Fazzalari NL (2011) Application of *in vivo* micro-computed tomography in the temporal characterisation of subchondral bone architecture in a rat model of low-dose monosodium iodoacetate-induced osteoarthritis. *Arthritis Res Ther* 13:R210.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue and also through web search engines, unless permission has been granted by the university to restrict access for a period of time.

Geetha Mohan

Date

---

## ACKNOWLEDGEMENTS

I would like to acknowledge the endless support of my supervisors, Professor Nick Fazzalari, Dr Julia Kuliwaba and Dr Ian Parkinson. Their expertise, ideas, enthusiastic encouragement and constructive comments have been invaluable throughout my candidature. I thank them for their mentorship, guidance and all the wonderful opportunities they have provided me to grow as a researcher.

I would like to express my sincere gratitude to Dr Egon Perilli who was instrumental in developing the *in vivo* micro-CT scan protocols. It was a pleasure knowing him and working with him. I will always value his advice, friendship, and optimism. I am grateful to Dr Julia Humphries for helping me with the biomarker analysis. I thank her for her time, friendship, and support. My sincere and heartfelt thanks to Lena Truong for her patience, care, friendship, and continuous encouragement. I thank her for making the late night lab work less cumbersome with all the wonderful conversations and laughs. It was very nice of her to share this lonely journey with me. I am thankful to Mrs Helen Tsangari, Ms Cheryl Ghan and Mrs Yolandi Starzak for their help with histology, wonderful company and support. I am thankful to Duminda Kumarasinghe, Clare Jones, Melissa Cantley, Pranay Sharma, and Balaji Seshadri for their friendship, support, and constant encouragement throughout these years.

I am greatly indebted to Dr Cally Guerin for her support, encouragement and perspectives that greatly helped me to develop an understanding of the academic, linguistic and cultural conventions relating to postgraduate research at The University of

---

---

Adelaide. I thank her for including me during happy occasions with her family which was heart-warming and a rewarding cultural experience. I am grateful to Dr Tim Kuchel, Dr Allan Rofe, Dr Dorota Gancarz, Brian Lewis and the staff at the Animal Care Facility for their generous assistance with animal work. I am likewise grateful to Mr John Terlet, Ms Ruth Williams and staff at the Adelaide Microscopy for their generous assistance and advice during *in vivo* micro-CT scans. I acknowledge the Endeavour Postgraduate award, a generous scholarship for my Ph.D provided by the Australian Government, Department of Education, Employment and Workplace Relations. I also acknowledge funding from Bone and Joint Research Laboratory and SA pathology, Adelaide, Australia for my project. I thank the case managers from Austraining International for their support and advice during my Ph.D.

Above all I would like to express my deepest gratitude to my parents for their unconditional love, strong support and encouragement. Their strong belief in me has always motivated me to strive for greater achievements in life. I thank my grandparents, sister Sathyavathi and brother Padmanabhan for understanding me and supporting me in my endeavour. Special thanks to my uncles, aunts, cousins and family friends in India for their well wishes for the successful completion of my Ph.D in Australia.

---

**PUBLISHED ABSTRACTS (reviewed)**

**Mohan G**, Perilli E, Kuliwaba JS, Parkinson IH, Humphries JH, Fazzalari NL (2011)  
Characterisation of temporal subchondral bone changes in a rat model of low-dose  
monosodium iodoacetate induced osteoarthritis: An *in vivo* micro-CT study.  
*Osteoarthritis Cartilage* 19:S61-S62.

**Mohan G**, Perilli E, Kuliwaba JS, Parkinson IH, Humphries JH, Fazzalari NL (2011)  
Alendronate treatment reduces tibial subchondral bone damage in early-stage  
osteoarthritis: An *in vivo* micro-CT study in a rodent model. *Osteoporos Int* 22:S579.

---

## SCIENTIFIC COMMUNICATION

**Mohan G**, Perilli E, Kuliwaba JS, Parkinson IH, Humphries JM, Fazzalari NL. Positive Effect of Alendronate on Tibial Subchondral Bone loss and Cartilage Repair at early stage experimental osteoarthritis in rats. *2011 Annual Scientific and Clinical Meeting & Annual General Meeting of the Australian Rheumatology Association (ARA) (South Australian Branch)*. Adelaide, Australia, October 28, 2011.

**Mohan G**, Perilli E, Kuliwaba JS, Parkinson IH, Humphries JM, Fazzalari NL. Characterisation of temporal subchondral bone changes in a rat model of low-dose monosodium iodoacetate induced osteoarthritis: An *in vivo* micro-CT study. *2011 OARSI world congress of Osteoarthritis Research Society International (OARSI)*. San Diego, CA, USA, September 15 – 18, 2011.

Mohan G, Perilli E, Kuliwaba JS, **Parkinson IH**, Humphries JM, Fazzalari NL. Alendronate treatment reduces tibial subchondral bone damage at early-stage osteoarthritis: an *in vivo* micro-CT study in a rodent model. *The 21st Annual Scientific Meeting of the Australian and New Zealand Bone and Mineral Society (ANZBMS)*. Gold Coast, Australia, September 4 – 8, 2011.

---

Mohan G, Perilli E, Kuliwaba JS, **Parkinson IH**, Humphries JM, Fazzalari NL. Tibial subchondral bone damage in early-stage osteoarthritis is reduced by Alendronate administration: an *in vivo* micro-CT study in a rodent model. *17th Annual Scientific Meeting of the Australian & New Zealand Orthopaedic Research Society (ANZORS)*. Brisbane, Queensland, Australia, September 1 – 2, 2011.

**Mohan G**, Perilli E, Kuliwaba JS, Parkinson IH, Humphries JM, Fazzalari NL. Alendronate inhibits early subchondral bone loss and joint discomfort by modulating the RANKL/OPG nexus in a rodent model of osteoarthritis. *The University of Adelaide, Faculty of Health Sciences Postgraduate Research Conference*. Adelaide, Australia, August 25, 2011.

**Mohan G**, Perilli E, Kuliwaba JS, Parkinson IH, Humphries JM, Fazzalari NL. Anti-resorptive efficacy of alendronate treatment on tibial subchondral bone at early-stage osteoarthritis: an *in vivo* micro-CT study in a rodent model. *Annual scientific meeting of the Australian Society for Medical Research SA Scientific Meeting (ASMR) (South Australian Division)*. Adelaide, Australia, June 8, 2011.

**Mohan G**, Perilli E, Kuliwaba JS, Humphries JM, Parkinson IH, Fazzalari NL. Application of *in vivo* micro-computed tomography in the characterisation of a rat model of osteoarthritis. *The 16th Annual Scientific Meeting of the ANZORS*. Melbourne, Australia, November 14 – 18, 2010.

---

**Mohan G**, Perilli E, Kuliwaba JS, Humphries JM, Parkinson IH, Fazzalari NL. Characterisation of a non-trauma rat model of iodoacetate induced osteoarthritis. *2010 Annual Scientific meeting of the ARA (South Australian Branch)*. Adelaide, Australia, October 22, 2010.

**Mohan G**, Perilli E, Kuliwaba JS, Humphries JM, Parkinson IH, Fazzalari NL. *In vivo* imaging of subchondral bone using micro-CT in a rodent model of osteoarthritis. *The 20th Annual Scientific Meeting of the ANZBMS*. Adelaide, Australia, September 5 – 8, 2010.

**Mohan G**, Perilli E, Kuliwaba JS, Humphries JM, Parkinson IH, Fazzalari NL. Characterisation of articular cartilage and subchondral bone changes in a non-trauma rat model of osteoarthritis. *The Annual Scientific Meeting of the Australian Orthopaedic Association (AOA) (South Australian Branch)*. Adelaide, Australia, August 13, 2010.

**Mohan G**, Perilli E, Kuliwaba JS, Humphries JM, Parkinson IH, Fazzalari NL. *In vivo* imaging of subchondral bone using micro computed tomography: A novel method to track longitudinal changes in a rodent model of osteoarthritis. Annual scientific meeting of the ASMR (*South Australian Division*). Adelaide, Australia, June 9, 2010.

---

**Mohan G,** Perilli E, Kuliwaba JS, Humphries JM, Parkinson IH, Fazzalari NL. Articular cartilage and subchondral bone changes in the monosodium iodoacetate rat model of osteoarthritis: A dose-response study. *The Sixth Clare Valley Bone Meeting*. Clare, Australia, March 26 – 30, 2010.

**Mohan G,** Perilli E, Kuliwaba JS, Parkinson IH, Fazzalari NL. Cartilage and subchondral bone changes in osteoarthritis: *In vivo* Micro-CT, Serological, and Histological Evaluation in a Rodent Model. *2009 Annual Scientific meeting of the ARA (South Australian Branch)*. Adelaide, Australia, November 6, 2009.

**Mohan G,** Perilli E, Kuliwaba JS, Parkinson IH, Fazzalari NL. Cartilage and subchondral bone changes in osteoarthritis: *in vivo* micro-CT, serological and histological evaluation in a rodent. *15th Annual Scientific Meeting of the ANZORS*. Adelaide, Australia, October 8 – 10, 2009.

**Mohan G,** Perilli E, Kuliwaba JS, Parkinson IH, Fazzalari NL. Longitudinal subchondral bone changes in a rodent model of osteoarthritis using *in vivo* micro-computed tomography. *Annual scientific meeting of the ASMR (South Australian Division)*. Adelaide, Australia, June 2, 2009.



---

## AWARDS

The following awards were received for original work in this thesis:

**Best poster presentation award** at The University of Adelaide, Faculty of Health Sciences Postgraduate Research Conference. Adelaide, Australia, August 25, 2011.

**ANZORS Travel award** at the 16th Annual Scientific Meeting of the Australian & New Zealand Orthopaedic Research Society (ANZORS). Melbourne, Australia, November 14 – 18, 2010.

**The Philip Alpers award** at the 2009 Annual Scientific and Clinical Meeting & Annual General Meeting of the Australian Rheumatology Association (ARA) (South Australian Branch). Adelaide, Australia, November 6, 2009.

---

## ABBREVIATIONS

2D	Two dimensional
3D	Three dimensional
ACLТ	Anterior cruciate ligament transection
ADAMTS	A disintegrin and metalloproteinase with thrombospondin motifs
ALN	Alendronate
BML	Bone marrow lesions
BMP	Bone morphogenetic proteins
BV	Bone volume
BV/TV	Bone volume fraction
COMP	Cartilage oligomeric matrix protein
CRP	C-reactive protein
CT	Cycle threshold
CTX-I	C-terminal telopeptide of collagen type I
CTX-II	C-terminal telopeptide of collagen type II
DEXA	Dual energy x-ray absorptiometry
Dkk-1	Dickkopf-1
FE	Finite element
GAPDH	Glyceraldehyde-3-phosphate dehydrogenase
HLWB	Hind limb weight-bearing
IL-1	Interleukin-1
KVp	Kilovoltage peak
MAPK	Mitogen activated protein kinase

---

MAR	Mineral apposition rate
MIA	Monosodium iodoacetate
Micro-CT	Micro computed tomography
ml	Millilitres
mm	Millimetre
MMPs	Metalloproteinases
MRI	Magnetic resonance imaging
NFAT	Nuclear factor of activated T cells,
NTX	N-terminal type I collagen telopeptides
OA	Osteoarthritis
OARSI	Osteoarthritis Research Society International
°C	degrees Celsius
OPG	Osteoprotegerin
OVX	Ovariectomized
Pl.Por	Plate porosity
Pl.Th	Plate thickness
RANK	Receptor activator of nuclear factor $\kappa$ B
RANKL	Receptor activator of nuclear factor $\kappa$ B ligand
ROI	Region of interest
RT	Reverse transcription
SPECT	Single-photon–emission computed tomography
Tb.N	Trabecular number
Tb.Sp	Trabecular separation
Tb.Th	Trabecular thickness

---

---

TGF- $\beta$	Transforming growth factor- $\beta$
TNF $\alpha$	Tumor necrosis factor alpha
TRAF	TNFR-associated factor proteins
TRAP	Tartrate-resistant acid phosphatase
vBMD	Volumetric bone mineral density
VEGF	Vascular endothelial growth factor
VOI	Volume of interest
Wnt	Wingless-type MMTV integration site
$\mu$ A	Microampere
$\mu$ l	Micro litres
$\mu$ m	Micrometres